Gut microbiota and outcomes in DLBCL, NFIA-ETO2 fusion cooperates with TP53 in leukemogenesis, and the impact of nirmatrelvir + ritonavir on CLL patient outcomes during the Omicron surge
Blood Podcast
00:00
The Role of the Gut Microbiota in DLBCL
In one earlier study, investigators found that the majority of DLBCL patients had Gut dysbiosis involving the proteobacteria phylum. A separate investigation in DLBCL and follicular lymphoma revealed that microbial dysbiosis was linked to aggressive histology and adverse clinical outcomes. Patients who responded to treatment tended to have greater Gut Microbiota diversity prior to treatment - numbers were small.
Transcript
Play full episode
